IP Library Granted Patent US 11,583,675
Granted Patent B2
US 11,583,675 · App. 16/506,633 · Granted Feb 21, 2023

Inhibiting viral infection using alternating electric fields

Inventors: Noa Kaynan (Kibbutz Barkai, IL); Tali Voloshin-Sela (Kibbutz Gvat, IL); Moshe Giladi (Moshav Herut, IL); Eilon Kirson (Ramat Hasharon, IL)
A61N1/32A61M37/00A61M2205/054
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,583,675
App. No.
16/506,633
Granted
Feb 21, 2023
Kind
B2
Abstract

Viral infections in a target region can be inhibited by imposing an alternating electric field in the target region for a duration of time. The alternating electric field has a frequency and a field strength such that when the alternating electric field is imposed in the target region for the duration of time, the alternating electric field inhibits infection of the cells in the target region by the virus. Optionally, the inhibition of viral infections using the alternating electric field approach can be combined with delivering an antiviral agent to the target region so that a therapeutically effective dose of the antiviral agent is present in the target region while the alternating electric fields are imposed.

Claims (18)

1. A method of inhibiting a virus from infecting cells in a target region, comprising the steps of:

imposing an alternating electric field in the target region for a duration of time, the alternating electric field having a frequency and a field strength, wherein when the alternating electric field is imposed in the target region for the duration of time, the alternating electric field inhibits infection of the cells in the target region by the virus,

wherein the target region is tumor-free.

2. The method of claim 1 , wherein the target region is a region within a live subject, and wherein the alternating electric field is safe for the subject.

3. The method of claim 2 , further comprising a step of delivering an antiviral agent to the target region so that a therapeutically effective dose of the antiviral agent is present in the target region while the imposing is performed.

4. The method of claim 1 , further comprising the step of delivering an antiviral agent to the target region so that the antiviral agent is present in the target region while the imposing is performed.

5. The method of claim 1 , wherein the alternating electric field has a frequency between 50 and 500 kHz.

6. The method of claim 1 , wherein the alternating electric field has a frequency between 25 kHz and 1 MHz.

7. The method of claim 1 , wherein the alternating electric field has a frequency of about 200 kHz.

8. The method of claim 1 , wherein the alternating electric field has a field strength between 1 and 5 V/cm RMS.

9. The method of claim 1 , wherein the alternating electric field has a field strength of about 1.2 V/cm RMS.

10. The method of claim 1 , wherein the duration of time is between 1 and 48 hours.

11. The method of claim 1 , wherein the duration of time is between 2 and 14 days.

12. The method of claim 1 , wherein the duration of time is about 48 hours.

13. The method of claim 1 , wherein the alternating electric field has an orientation that is repeatedly switched between at least two directions during the duration of time.

14. The method of claim 13 , wherein the orientation of the alternating electric field is switched about once a second.

15. The method of claim 1 , wherein the alternating electric field has an orientation that is repeatedly switched between a first direction and a second direction during the duration of time, wherein the first direction is roughly perpendicular to the second direction.

16. The method of claim 1 , wherein the alternating electric field is applied to the target region via capacitively coupled electrodes.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2021
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 057563/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: GILADI, MOSHE; KAYNAN, NOA; VOLOSHIN, TALI; KIRSON, EILON D.
To: NOVOCURE LIMITED
Reel/Frame 056273/0721 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →